Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Galectin-3 protein is critical to the development of liver fibrosis because galectin-3 null mice have attenuated fibrosis after liver injury. Therefore, we examined the ability of novel complex carbohydrate galectin inhibitors to treat toxin-induced fibrosis and cirrhosis. Fibrosis was induced in rats by intraperitoneal injections with thioacetamide (TAA) and groups were treated with vehicle, GR-MD-02 (galactoarabino-rhamnogalaturonan) or GM-CT-01 (galactomannan). In initial experiments, 4 weeks of treatment with GR-MD-02 following completion of 8 weeks of TAA significantly reduced collagen content by almost 50% based on Sirius red staining. Rats were then exposed to more intense and longer TAA treatment, which included either GR-MD-02 or GM-CT-01 during weeks 8 through 11. TAA rats treated with vehicle developed extensive fibrosis and pathological stage 6 Ishak fibrosis, or cirrhosis. Treatment with either GR-MD-02 (90 mg/kg ip) or GM-CT-01 (180 mg/kg ip) given once weekly during weeks 8-11 led to marked reduction in fibrosis with reduction in portal and septal galectin-3 positive macrophages and reduction in portal pressure. Vehicle-treated animals had cirrhosis whereas in the treated animals the fibrosis stage was significantly reduced, with evidence of resolved or resolving cirrhosis and reduced portal inflammation and ballooning. In this model of toxin-induced liver fibrosis, treatment with two galectin protein inhibitors with different chemical compositions significantly reduced fibrosis, reversed cirrhosis, reduced galectin-3 expressing portal and septal macrophages, and reduced portal pressure. These findings suggest a potential role of these drugs in human liver fibrosis and cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Self-citationRamachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 1×
“Recently, a new subtype of M2macrophages was identified that is critical for resolution of fibrosis in the liver [45].”
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562 · cited 3×
“Based on these and other studies in kidney [11,18], lung [10], and heart [19], galectin-3 appears to be integral to accumulation of fibrosis in parenchymal tissue.”
BackgroundN-Glycans in cancer progression
Lau, K. S., & Dennis, J. W. (2008) · Glycobiology · doi:10.1093/glycob/cwn071 · Cited by 390 · cited 1×
“Binding of galectin-3 to N-glycans has been connected to multiple cellular processes including cell adhesion and migration, immune cell function, inflammation, and neoplasia [5,26–30].”
Background
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citationHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Self-citationLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Dose-dependent reduction of NAS, fibrosis and portal pressure in rat and murine models of NASH potentially due to an impact on macrophage polarization and reduced activation of HSCs [349,350].”
BackgroundLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Self-citationJu, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
“The belapectin treatment of rats with advanced fibrosis and cirrhosis induced by thioacetamide resulted in a reduction of collagen to below 10%, a reversal of cirrhosis, and reduced portal hypertension.(16) A Phase 1 study has shown that belapectin is safe and well tolerated at single and multiple doses of 2, 4, and 8…”
BackgroundSelf-citationLefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
“The TAA model is commonly used for the evaluation of treatment at various stages of disease, from inflammation to cirrhosis [36].”
MethodSelf-citationTissue mechanics regulate brain development, homeostasis and disease
Barnes, J. M., Przybyla, L., & Weaver, V. M. (2017) · Journal of Cell Science · doi:10.1242/jcs.191742 · Cited by 316
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens
Díaz-Alvarez, L., & Ortega, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/9247574 · Cited by 262
Functions of Galectin-3 and Its Role in Fibrotic Diseases
Li, L.-C., Li, J., & Gao, J. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218370 · Cited by 261
Liver fibrosis: Pathophysiology and clinical implications
Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1499 · Cited by 259
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Mariño, K. V., Cagnoni, A. J., Croci, D. O., & Rabinovich, G. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00636-2 · Cited by 246
Standard Operating Procedures in Experimental Liver Research: Thioacetamide model in mice and rats
Wallace, M., Hamesch, K., Lunova, M., Kim, Y., Weiskirchen, R., Strnad, P., & Friedman, S. (2015) · Laboratory Animals · doi:10.1177/0023677215573040 · Cited by 210
Self-citationManagement Strategies for Liver Fibrosis
Altamirano-Barrera, A., Barranco-Fragoso, B., & Méndez-Sánchez, N. (2017) · Annals of Hepatology · doi:10.5604/16652681.1226814 · Cited by 191
Targeting galectin-3 in inflammatory and fibrotic diseases
Bouffette, S., Botez, I., & De Ceuninck, F. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.001 · Cited by 165
The therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Self-citation
Metadata
- Authors
- Traber, P. G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.-I., & Friedman, S. L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-09
- Volume
- 8
- Issue
- 10
- Pages
- e75361
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2141016294
- Cited by
- 214
- References
- 4
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.